164 related articles for article (PubMed ID: 32290439)
1. Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients.
Madsen AT; Winther-Larsen A; McCulloch T; Meldgaard P; Sorensen BS
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32290439
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
Remon J; Swalduz A; Planchard D; Ortiz-Cuaran S; Mezquita L; Lacroix L; Jovelet C; Rouleau E; Leonce C; De Kievit F; Morris C; Jones G; Mercier K; Howarth K; Green E; Pérol M; Saintigny P; Besse B
PLoS One; 2020; 15(6):e0234302. PubMed ID: 32525942
[TBL] [Abstract][Full Text] [Related]
3. Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in
Dietz S; Christopoulos P; Gu L; Volckmar AL; Endris V; Yuan Z; Ogrodnik SJ; Zemojtel T; Heussel CP; Schneider MA; Meister M; Muley T; Reck M; Schlesner M; Thomas M; Stenzinger A; Sültmann H
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31753813
[TBL] [Abstract][Full Text] [Related]
4. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
[TBL] [Abstract][Full Text] [Related]
5. Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer.
Zhang EW; Dagogo-Jack I; Kuo A; Rooney MM; Shaw AT; Digumarthy SR
Cancer; 2020 Oct; 126(20):4473-4484. PubMed ID: 32757294
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
7. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
8. Acquired
Yao B; Han X; Pang L; Xu C; Liu S; Cheng X; Chen J
Onco Targets Ther; 2021; 14():4329-4333. PubMed ID: 34376997
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer.
Yang H; Zhang J; Zhang L; Wen X; Luo Y; Yao D; Cheng T; Cheng H; Wang H; Lou F; Guo J; Liang X; Cao S; Chen J
Oncol Lett; 2019 Nov; 18(5):4762-4770. PubMed ID: 31611986
[TBL] [Abstract][Full Text] [Related]
12. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Guibert N; Jones G; Beeler JF; Plagnol V; Morris C; Mourlanette J; Delaunay M; Keller L; Rouquette I; Favre G; Pradines A; Mazieres J
Lung Cancer; 2019 Nov; 137():1-6. PubMed ID: 31518912
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.
Herrera AF; Kim HT; Kong KA; Faham M; Sun H; Sohani AR; Alyea EP; Carlton VE; Chen YB; Cutler CS; Ho VT; Koreth J; Kotwaliwale C; Nikiforow S; Ritz J; Rodig SJ; Soiffer RJ; Antin JH; Armand P
Br J Haematol; 2016 Dec; 175(5):841-850. PubMed ID: 27711974
[TBL] [Abstract][Full Text] [Related]
14. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
15. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
17. Serial Monitoring of Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer to Predict the Therapeutic Response.
Jia N; Sun Z; Gao X; Cheng Y; Zhou Y; Shen C; Chen W; Wang X; Shi R; Li N; Zhou J; Bai C
Front Genet; 2019; 10():470. PubMed ID: 31164904
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic decision based on molecular detection of resistance mechanism in an ALK-rearranged lung cancer patient: a case report.
De Carlo E; Schiappacassi M; Urbani M; Doliana R; Baldassarre G; Da Ros V; Santarossa S; Chimienti E; Berto E; Fratino L; Bearz A
Onco Targets Ther; 2018; 11():8945-8950. PubMed ID: 30573982
[TBL] [Abstract][Full Text] [Related]
19. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Goldberg SB; Narayan A; Kole AJ; Decker RH; Teysir J; Carriero NJ; Lee A; Nemati R; Nath SK; Mane SM; Deng Y; Sukumar N; Zelterman D; Boffa DJ; Politi K; Gettinger SN; Wilson LD; Herbst RS; Patel AA
Clin Cancer Res; 2018 Apr; 24(8):1872-1880. PubMed ID: 29330207
[No Abstract] [Full Text] [Related]
20. Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing.
Wang B; Fan Y; Zhang L; Liu L; Ma Y; Ma X; Huang Y; Wu Y; Liang Y; Xu Y; Wu X
Clin Med Insights Oncol; 2022; 16():11795549221075326. PubMed ID: 35197718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
